Brief: Ascletis Pharma Selects Fixed-Dose Combination Of Asc48 And Asc30 For Clinical Development
15/07/2026 11:22
BRIEF-Ascletis Pharma Selects Fixed-Dose Combination Of Asc48 And Asc30 For Clinical Development July 15 (Reuters) - Ascletis Pharma Inc 1672.HK:
SELECTS FIXED-DOSE COMBINATION OF ASC48 AND ASC30 FOR CLINICAL DEVELOPMENT
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management